MiniMed Group (NASDAQ:MMED) Price Target Raised to $26.00

MiniMed Group (NASDAQ:MMED) had its price objective lifted by Citigroup from $23.00 to $26.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts also recently weighed in on MMED. BTIG Research raised their price target on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company upped their price objective on MiniMed Group from $22.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday. Weiss Ratings upgraded MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Bank of America raised their price objective on MiniMed Group from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Benchmark restated a “buy” rating on shares of MiniMed Group in a research report on Thursday, June 4th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.77.

MiniMed Group Stock Down 2.3%

Shares of NASDAQ:MMED opened at $23.28 on Wednesday. The business has a fifty day moving average of $18.21. The company has a market cap of $6.55 billion and a price-to-earnings ratio of -34.24. MiniMed Group has a one year low of $10.65 and a one year high of $24.43.

MiniMed Group (NASDAQ:MMED) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million for the quarter. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, research analysts forecast that MiniMed Group will post 0.7 earnings per share for the current fiscal year.

Institutional Trading of MiniMed Group

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new position in shares of MiniMed Group in the second quarter valued at about $1,058,000. Deutsche Bank AG purchased a new stake in shares of MiniMed Group during the second quarter worth about $420,000. BlackRock Inc. grew its stake in shares of MiniMed Group by 7,527.5% in the second quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock worth $29,848,000 after purchasing an additional 1,970,314 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in MiniMed Group during the 2nd quarter valued at about $185,000. Finally, Legal & General Group Plc purchased a new position in MiniMed Group during the 2nd quarter valued at about $91,000.

Key Stories Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Analysts see further upside: Citigroup and Wells Fargo issued forecasts calling for strong price appreciation, while analysts at Mizuho, UBS Group, Bank of America and BTIG Research also said MiniMed’s share price is expected to rise. The cluster of bullish views may support investor confidence and buying interest. Citigroup forecast Wells Fargo forecast Mizuho analyst view UBS analyst view Bank of America analyst view BTIG analyst view
• Positive Sentiment: New products are driving optimism: A recent product introduction helped lift MiniMed’s top line, with further launches scheduled over the coming months. Investors appear to be viewing the product pipeline as a potential source of sustained growth. Why MiniMed stock was soaring
• Positive Sentiment: Operational momentum is improving: Coverage highlights recurring revenue streams, regulatory progress and a strong beginning to fiscal 2027, reinforcing the case for more predictable growth. Recurring revenues and product cycle Fiscal 2027 progress
• Neutral Sentiment: Morgan Stanley raised its target: The firm increased its target from $19 to $21 and maintained an “overweight” rating. However, the new target remains below the referenced recent trading level, suggesting that some expected gains may already be reflected in the valuation.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.